## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/000749

Α.	CLASSIFICATION OF SUBJECT MATTER						
Int. Cl. 7:	C12Q 1/68 C12N 15/00 A01K 67/00						
According to	International Patent Classification (IPC) or to bo	th nation	al classification	on and	1 IPC		
В.	FIELDS SEARCHED						
	umentation searched (classification system followed by nic database	classifica	tion symbols)				
	n searched other than minimum documentation to the c nic database	xtent that	such documen	its are	included in	the fields sear	ched
Electronic das WPIDS; M	a base consulted during the international search (name EDLINE; CAPLUS: SOCS, suppressor cytol	of data ba cine sign	se and, where aling, G-CS	practic F, gr	able, scarci anulocyte	terms used) colony stir	nulating factor
C.	DOCUMENTS CONSIDERED TO BE RELEVANT	•					
Category*	Citation of document, with indication, where a	рргоргіа	te, of the rele	vant p	assages		Relevant to claim No.
Χ	Matsumoto et al (2003) 'A role of suppres (SOCS3/CIS3/SSI3) in CD28-mediated In The Journal of Experimental Medicine. V See in particular 4th paragraph, page 427	nterleuki	n 2 Product		3		16, 17
X, Y	Croker et al (2003) 'SOCS3 negatively re Nature Immunology. Vol 4(6): 540-545 Published online May 18 2003 See in particular page 541	gulates I	L-6 signalin	ng in 1	vivoʻ		16, 17
X	Further documents are listed in the continua	tion of E	Box C		See pate	nt family ar	nex
"A" docu	al categories of cited documents: Thent defining the general state of the art which is "T" onsidered to be of particular relevance	conflict	ument published with the applical ng the invention	tion but			r priority date and not in ciple or theory
	r application or patent but published on or after the "X" ational filing date						not be considered novel he document is taken
or wi	ment which may throw doubts on priority claim(s)  "Y" which is cited to establish the publication date of  the citation or other special reason (as specified)	docume involve	an inventive step	p when	the documer	it is combined w	not be considered to with one or more other on skilled in the art
"O" docu or ot	ment referring to an oral disclosure, use, exhibition her means ment published prior to the international filing date	docume	nt member of the	e same	patent family	,	
but I	ater than the priority date claimed	1.					
Date of the	actual completion of the international scarch	Da	ite of mailing o	of the i	nternationa	l search report	2.6 AUG 2004
1	nailing address of the ISA/AU	Aı	thorized office	cr			
PO BOX 20 E-mail adds	AN PATENT OFFICE 10. WODEN ACT 2606, AUSTRALIA ess: pct@ipaustralia.gov.au 10. (02) 6285 3929	1	EXTE PRE		5283 267°	7 .	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/000749

FC1/AG2004						
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT						
Citation of document, with indication, where appropriate, of the relevant passages						
Georgiades et al (2002) 'vavCre Trangenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages)' Genesis. Vol 34: 251-256 See the whole document						
Hörtner et al (2002) 'Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction' The Journal of Immunology. Vol 169: 1219-1227 See the whole document	13 to 15					
Hermans et al (2003) 'Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid cells'  Blood. Vol 101(7): 2584-2590 See the whole document	13 to 15					
Croker et al (2004) 'SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis' Inimunity. Vol 20: 153-165 See the whole document	1 to 17					
Kimura et al (2004) 'SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling' The Journal of Biological Chemistry. Vol 279(8): 6905-6910 See the whole document	1 to 17					
Van de Geijn et al (2004) 'Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling' Journal of Leukocyte Biology. Vol 76: 237-244 See the whole document	1 to 15					
Van de Geijn et al (2004) 'G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact' Blood. Vol 104(3): 667-674 See the whole document	1 to 15					
	Georgiades et al (2002) 'vavCre Trangenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages)' Genesis. Vol 34: 251-256 See the whole document  Hörtner et al (2002) 'Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction' The Journal of Immunology. Vol 169: 1219-1227 See the whole document  Hermans et al (2003) 'Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid cells' Blood. Vol 101(7): 2584-2590 See the whole document  Croker et al (2004) 'SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis' Immunity. Vol 20: 153-165 See the whole document  Kimura et al (2004) 'SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling' The Journal of Biological Chemistry. Vol 279(8): 6905-6910 See the whole document  Van de Geijn et al (2004) 'Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling' Journal of Leukocyte Biology. Vol 76: 237-244 See the whole document  Van de Geijn et al (2004) 'G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact' Blood. Vol 104(3): 667-674					

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/000749

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: V

Claims 1 to 12 relate to a disproportionately large number of possible compounds which are not supported by the description according to Article 6 PCT or can be considered disclosed according to Article 5 PCT. Claims 1 to 12 lack the appropriate support and the patent application lacks the required disclosure to such an extent that a meaningful search encompassing the entire scope of claims 1-12 is impossible. For this reason the search was directed at the inventive concept of the invention which appears to be the use of a transgenic animal with altered levels of SOCS3 to determine compounds that modulate G-CSF activity by modulating SOCS3 activity.

The Applicant's attention is drawn to the fact that claims, or parts of claims relating to inventions in respect of which no International Search Report has been established need not be the subject of an International Preliminary Examination.